Deals Of The Week: AstraZeneca/Regulus, Biogen Idec/Regulus, Pfizer/AstraZeneca, Elan/Neotope
Next-wave patient-based research pioneer PatientsLikeMe struck an alliance with Merck to “evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.”
You may also be interested in...
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.